Successful use of obinutuzumab in focal segmental glomerulosclerosis with inadequate response to rituximab: a case report
{{output}}
Introduction: Podocytopathies such as minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) remain therapeutic challenges in adults. Although corticosteroids and rituximab (RTX), a chimeric anti-CD20 monoclon... ...
